Uncertainties in pharmacokinetic modeling for perchloroethylene. I. Comparison of model structure, parameters, and predictions for low-dose metabolism rates for models derived by different authors
- PMID: 2236748
- DOI: 10.1111/j.1539-6924.1990.tb00528.x
Uncertainties in pharmacokinetic modeling for perchloroethylene. I. Comparison of model structure, parameters, and predictions for low-dose metabolism rates for models derived by different authors
Abstract
In recent years physiologically based pharmacokinetic models have come to play an increasingly important role in risk assessment for carcinogens. The hope is that they can help open the black box between external exposure and carcinogenic effects to experimental observations, and improve both high-dose to low-dose and interspecies projections of risk. However, to date, there have been only relatively preliminary efforts to assess the uncertainties in current modeling results. In this paper we compare the physiologically based pharmacokinetic models (and model predictions of risk-related overall metabolism) that have been produced by seven different sets of authors for perchloroethylene (tetrachloroethylene). The most striking conclusion from the data is that most of the differences in risk-related model predictions are attributable to the choice of the data sets used for calibrating the metabolic parameters. Second, it is clear that the bottom-line differences among the model predictions are appreciable. Overall, the ratios of low-dose human to bioassay rodent metabolism spanned a 30-fold range for the six available human/rat comparisons, and the seven predicted ratios of low-dose human to bioassay mouse metabolism spanned a 13-fold range. (The greater range for the rat/human comparison is attributable to a structural assumption by one author group of competing linear and saturable pathways, and their conclusion that the dangerous saturable pathway constitutes a minor fraction of metabolism in rats.) It is clear that there are a number of opportunities for modelers to make different choices of model structure, interpretive assumptions, and calibrating data in the process of constructing pharmacokinetic models for use in estimating "delivered" or "biologically effective" dose for carcinogenesis risk assessments. We believe that in presenting the results of such modeling studies, it is important for researchers to explore the results of alternative, reasonably likely approaches for interpreting the available data--and either show that any conclusions they make are relatively insensitive to particular interpretive choices, or to acknowledge the differences in conclusions that would result from plausible alternative views of the world.
Similar articles
-
Evaluation of physiologically based pharmacokinetic models in risk assessment: an example with perchloroethylene.Crit Rev Toxicol. 2005 Jun;35(5):413-33. doi: 10.1080/10408440590931994. Crit Rev Toxicol. 2005. PMID: 16097137 Review.
-
Uncertainties in pharmacokinetic modeling for perchloroethylene: II. Comparison of model predictions with data for a variety of different parameters.Risk Anal. 1993 Dec;13(6):599-610. doi: 10.1111/j.1539-6924.1993.tb01322.x. Risk Anal. 1993. PMID: 8310161 Review.
-
In vivo and in vitro studies of perchloroethylene metabolism for physiologically based pharmacokinetic modeling in rats, mice, and humans.Toxicol Appl Pharmacol. 1996 Feb;136(2):289-306. doi: 10.1006/taap.1996.0036. Toxicol Appl Pharmacol. 1996. PMID: 8619237
-
Variability of physiologically based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene (PCE).Toxicol Lett. 1993 May;68(1-2):131-44. doi: 10.1016/0378-4274(93)90126-i. Toxicol Lett. 1993. PMID: 8516760
-
Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output.Toxicol Lett. 1989 Dec;49(2-3):371-85. doi: 10.1016/0378-4274(89)90044-1. Toxicol Lett. 1989. PMID: 2690411 Review.
Cited by
-
Fuzzy simulation of pharmacokinetic models: case study of whole body physiologically based model of diazepam.J Pharmacokinet Pharmacodyn. 2004 Jun;31(3):185-213. doi: 10.1023/b:jopa.0000039564.35602.78. J Pharmacokinet Pharmacodyn. 2004. PMID: 15518244
-
Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment.Environ Health Perspect. 2000 May;108 Suppl 2(Suppl 2):283-305. doi: 10.1289/ehp.00108s2283. Environ Health Perspect. 2000. PMID: 10807559 Free PMC article. Review.
-
Whole body pharmacokinetic models.Clin Pharmacokinet. 2003;42(10):883-908. doi: 10.2165/00003088-200342100-00002. Clin Pharmacokinet. 2003. PMID: 12885263 Review.
-
Applications of physiologic pharmacokinetic modeling in carcinogenic risk assessment.Environ Health Perspect. 1994 Dec;102 Suppl 11(Suppl 11):37-50. doi: 10.1289/ehp.94102s1137. Environ Health Perspect. 1994. PMID: 7737040 Free PMC article. Review.
-
Toxicity testing in the 21st century: a vision and a strategy.J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):51-138. doi: 10.1080/10937404.2010.483176. J Toxicol Environ Health B Crit Rev. 2010. PMID: 20574894 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources